Table 2.
Univariable regression with duration of readmissions and variables.
| Duration of readmissions |
|||
|---|---|---|---|
| Variables | β (×10−2) | 95% CI (×10−2) | P value |
| Total daily dose | 11.65 | 5.01, 18.29 | 0.001 |
| Number of medications | 24.14 | 11.96, 36.33 | <0.001 |
| Age (more than 75 year-old) | 206.02 | 94.63, 317.41 | <0.001 |
| Racea | |||
| If Malay | −215.53 | −358.48, −72.57 | 0.003 |
| If Indian | −175.48 | −340.42, −10.54 | 0.037 |
| If others | −285.96 | −486.00, −85.92 | 0.005 |
| Genderb | |||
| If female | 150.2 | −41.44, 258.95 | 0.007 |
| Co-morbiditiesc | |||
| Diabetes | −21.59 | −131.18, 88.00 | 0.699 |
| Hypertension | 193.13 | 80.75, 305.51 | 0.001 |
| Dyslipidemia | 110.91 | 1.95, 219.86 | 0.046 |
| CHD | 20.11 | −96.23, 136.46 | 0.734 |
| CVA | 158.98 | −0.90, 318.86 | 0.051 |
| CHF | 220.45 | −27.65, 468.56 | 0.081 |
| COPD | 137.91 | −86.41, 362.23 | 0.228 |
| Asthma | −159.96 | −344.09, 24.16 | 0.088 |
| Liver disease | −129.46 | −334.09, 75.18 | 0.215 |
| CKD | 203 | 36.65, 369.35 | 0.017 |
| Osteoarthritis | −67.65 | −294.77, 159.47 | 0.559 |
| Osteoporosis | −22.02 | −346.10, 302.06 | 0.894 |
| Gout | 115.65 | −99.24, 330.53 | 0.291 |
| Cataract | 30.67 | −199.20, 260.54 | 0.793 |
| Anemia | 46.43 | −83.73, 176.59 | 0.484 |
| Cancer | 154.5 | −30.97, 339.98 | 1.64 |
| BPH | 20.76 | −203.81, 245.32 | 0.856 |
| Thyroid disease | 102.33 | −146.24, 350.89 | 0.419 |
| Hem | 638.49 | −345.96, 1622.93 | 0.203 |
| Epilepsy | −149.47 | −413.65, 114.70 | 0.267 |
| Dementia | 171.75 | −32.70, 376.20 | 0.1 |
| Depression | 282.21 | 83.90, 480.51 | 0.005 |
| Alzheimer’s disease | −154.51 | −621.55, 312.52 | 0.516 |
| Schizophrenia | 66.25 | −193.90, 326.39 | 0.617 |
| PKD | 173.17 | −150.64, 496.97 | 0.294 |
| Hemiplegia | 8.03 | −520.88, 5.36.95 | 0.976 |
| Ulcer disease | −57.00 | −284.13, 170.14 | 0.622 |
| Number of comorbidities | 42.50 | 14.11, 70.88 | 0.003 |
| Types of DRPd | |||
| Non-compliance | 138.65 | −99.79, 377.10 | 0.254 |
| Hypoglycemia | −350.05 | −920.26, 220.16 | 0.228 |
| Hyponatremia | −231.63 | −1037.40, 574.14 | 0.573 |
| Hypokalemia | −13.57 | −1000.71, 973.58 | 0.978 |
| Metabolic alkalosis | −163.73 | −1556.56, 1229.09 | 0.818 |
| Dehydration | 322.84 | −247.47, 893.14 | 0.267 |
| Low blood pressure | −265.12 | −962.88, 432.64 | 0.456 |
| Giddiness | 36.8 | −588.04, 661.64 | 0.908 |
| LFT abnormalities | 38.51 | −658.70, 735.71 | 0.914 |
| N/V/D | 112.21 | −585.80, 810.22 | 0.752 |
| Constipation | 236.88 | −1155.88, 1629.65 | 0.739 |
| Anemia | 638.49 | −345.96, 1622.93 | 0.203 |
| Thrombocytopenia | 841.71 | 146.68, 1536.74 | 0.018 |
| Rashes | −214.81 | −912.67, 483.06 | 0.546 |
| Supratherapeutic dose | 296.48 | −257.12, 850.08 | 0.293 |
| Subtherapeutic dose | 437.19 | −955.29, 1829.67 | 0.538 |
Abbreviations: Coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD), cerebrovascular disease (CVD) benign prostatic hyperplasia (BPH), Parkinson’s disease (PKD), liver function test (LFT), nausea, vomiting, diarrhea (N/V/D), not significant (NS); p > 0.05, drug-related problem (DRP).
a
Chinese as reference group.
b
Male as reference group.
c
Absence of comorbidities as reference group.
d
Absence of DRP as reference group.